NRC to Hold Online Public Meeting on Proposed Medical Use Licensing Rule

The U.S. Nuclear Regulatory Commission recently announced it will hold an online public meeting from 1:00 p.m. to 2:30 p.m. Eastern Time on August 20 to introduce the proposed rule aimed at reducing barriers to medical use licensing. The proposed rule was published in the Federal Register on July 27. During the meeting, NRC staff will outline the key provisions of the rule and related implementation activities, and answer questions from the public. The meeting is open to the public and will focus on regulatory processes related to medical use licensing, with the goal of explaining and discussing the proposed rule and subsequent implementation arrangements...

2026-08-16

FDA Approves Tauklarify, a Tau PET Imaging Agent for Alzheimer's Disease

The U.S. Food and Drug Administration has approved Tauklarify, a new brain imaging agent for the evaluation of Alzheimer's disease. The drug, also known as MK-6240, is a radioactive diagnostic agent for positron emission tomography (PET) in adults, primarily indicated for adults with cognitive impairment who require physician assessment of abnormal tau protein accumulation in the brain. The twisted, insoluble fibrous deposits formed by tau protein are believed to be associated with neurodegenerative diseases such as Alzheimer's disease. The developer, Lantheus, stated that the safety of Tauklarify was evaluated in two clinical trials involving more than 1,700 subjects. Adverse reactions...

2026-08-16

Function Health Secures $450 Million in Funding to Expand Laboratory Testing and Medical Imaging Platform

U.S. health technology company Function Health recently secured $450 million in growth funding from General Catalyst's Customer Value Fund. The company stated that the funds will be used to expand user coverage of its testing and medical imaging platform. Function Health launched as a beta version in 2023, with a platform integrating laboratory testing, medical imaging, and health data analytics services. Its membership includes over 160 laboratory tests, with testing scheduled twice a year, and annual plans starting at $365. Testing coverage encompasses cardiovascular health, hormones, thyroid and kidney function, inflammation, nutritional levels, and certain cancers...

2026-08-16

Society of Interventional Radiology Launches Framework to Quantify the Value of Interventional Radiology

The Society of Interventional Radiology (SIR) is developing a framework to measure the clinical and economic value of interventional radiology, aiming to expand the specialty's role in health system planning, payment reimbursement, and patient management. According to reports, SIR has partnered with triLumen Health Partners to develop a strategic roadmap focused on identifying and quantifying the contributions of interventional radiology in academic medical centers, community hospitals, and outpatient settings. The project is expected to inform SIR's strategic planning extending through 2029 and beyond. Dr. Saher S. Sabri, SIR President, stated that interventional radiology is currently often evaluated using metrics such as procedure volume and relative value units, but these metrics may not fully reflect its role in long-term clinical care, perioperative management, and overall health system cost control...

2026-08-16

Bac Ninh Province, Vietnam, Issues Plan for Peaceful Use of Atomic Energy

The People's Committee of Bac Ninh Province, Vietnam, recently issued Plan No. 299/KH-UBND, deploying the implementation of the province's strategy for the peaceful use of atomic energy through 2035, with a vision toward 2050. Signed by Mai Son, Standing Vice Chairman of the Bac Ninh Provincial People's Committee, the plan aims to implement national strategic tasks in line with local conditions, enhance management efficiency in the atomic energy sector, and promote atomic energy in serving socioeconomic development while ensuring radiation safety, nuclear safety, and nuclear security. Under the plan, Bac Ninh Province will focus on advancing research and applications of radiation technology and radioisotopes in fields such as healthcare, agriculture, natural resources and environment, and industry, while strengthening the safety management of radiation sources. Relevant applications will serve...

2026-08-15

CGN Medical and West China Hospital of Sichuan University Sign Proton Therapy Innovation Technology Cooperation Agreement

On August 14, the 32nd China International Medical Instruments and Equipment Exhibition & Technology Exchange Conference (China-Hospeq 2026) opened at the China National Convention Center in Beijing. CGN Medical was invited to exhibit under the theme of "Precision Radiotherapy · Nuclear Medicine Empowerment," showcasing achievements in the healthcare sector including the Hezhi® proton therapy system and the Hejia® germanium-gallium generator. The exhibits covered radiotherapy solutions, new medical isotopes, SiPM chips for molecular imaging, radiation protection, and medical device sterilization. On the first day of the exhibition, representatives from relevant departments and institutions visited the CGN Medical booth, learning about CGN's product layout and technological progress in the nuclear medicine field, and showing interest in its efforts in the domestic substitution of high-end medical equipment...

2026-08-15

China Isotope & Radiation's National Headquarters for Irradiation Application Industry Settles in Guangzhou

On August 11, the national headquarters of China Isotope & Radiation's irradiation application industry — CNNC Irradiation (Guangdong) Technology Co., Ltd. (hereinafter referred to as "CNNC Irradiation") — officially settled in Tianhe District, Guangzhou, and entered the Pearl River New City. This marks an important milestone in the development of China Isotope & Radiation's irradiation application industry. The relocation of the national headquarters for irradiation application to Guangzhou is a key step for China Isotope & Radiation in implementing the central-local cooperation deployment between CNNC and Guangdong Province, and in strategically positioning for the "15th Five-Year Plan." As the nuclear technology application industry platform of CNNC, China Isotope & Radiation possesses a complete industrial chain and core technological advantages in the irradiation application field. It is a leading domestic provider of irradiation facility design, manufacturing, installation, and operation & maintenance services, and has accumulated extensive industrialization experience in high-end medical device sterilization, green irradiation processing of food and traditional Chinese medicinal materials, and material modification.

2026-08-14

OXOS Medical and Others Deploy Portable X-Ray Systems to Disaster Zones in Venezuela

On August 12, U.S.-based OXOS Medical announced that it will partner with the non-profit organization Love & Life Foundation and the rapid response and disaster intervention team MEDIC Corps to deploy the MC2 portable X-ray system to Venezuela to support post-disaster humanitarian medical relief efforts. According to reports, the strong earthquake that struck Venezuela on June 24 has caused more than 16,000 injuries. For medical teams treating patients on the front lines in rubble and disaster zones, timely assessment of injuries such as fractures and chest or abdominal trauma is critical, but in areas with damaged infrastructure and limited resources, routine medical imaging examinations are often difficult to obtain in a timely manner. The materials also cite World Health Organization data stating...

2026-08-13

US Valion Bio Initiates Safety Study of Entolimod for Radiation-Induced Gastrointestinal Injury

US biotechnology company Valion Bio announced on August 12 that the safety study of its investigational therapeutic candidate Entolimod for radiation-induced gastrointestinal injury is scheduled to commence this week. The study is being advanced by the Armed Forces Radiobiology Research Institute (AFRRI) under a contract with the National Institute of Allergy and Infectious Diseases (NIAID), as part of a government-funded research program. According to the company's disclosure, Entolimod has been delivered to AFRRI, the study has received approval from the Institutional Animal Care and Use Committee (IACUC), and the experimental animals are currently in the pre-dosing acclimation phase. The safety study will confirm the tolerability of Entolimod in the animal strain used by AFRRI...

2026-08-13

ASP Isotopes Plans Commercial Delivery of Multiple Stable Isotopes in Second Half of 2026

ASP Isotopes Inc. recently presented its expansion plans for isotope production, radiopharmaceuticals, and helium operations at Canaccord Genuity's 46th Annual Growth Conference. The company aims to begin commercial delivery of stable isotopes including silicon-28, carbon-14, and ytterbium-176 in the second half of 2026. Victor Petkov, the company's Chief Commercial Officer, stated that ASP Isotopes is leveraging its proprietary enrichment technology to serve electronics, nuclear medicine, and nuclear fuel-related markets. Currently, the company operates three production facilities in Pretoria, South Africa, primarily producing silicon-28 for semiconductor applications, as well as carbon-14 and ytterbium-176 for nuclear medicine-related uses. Regarding isotope supply...

2026-08-13

Anhui Juhe Haizhi Settles in Hefei, to Release Radiation-Related Maintenance Robots

Anhui Juhe Haizhi Technology Co., Ltd., jointly established by Jianghuai Laboratory, the Institute of Energy at Hefei Comprehensive National Science Center, Keda Silicon Valley, and Anhui Penggong Intelligent Equipment Technology Co., Ltd., has officially settled in Hefei. The company focuses on the industrialization of embodied intelligent equipment for extreme environments, with key deployments in high-risk operational scenarios such as nuclear radiation, deep sea, and specialty chemicals. Juhe Haizhi plans to release two embodied intelligent robots for extreme environments by the end of August 2026. Among them, the commercial fusion radiation-resistant maintenance robot is one of the key products to be released, providing unmanned intelligent maintenance solutions for nuclear radiation-related scenarios, with neutron target maintenance for Boron Neutron Capture Therapy (BNCT) devices being one of its core application scenarios...

2026-08-13

Maistop Completes Pre-A Round Financing to Advance Medical Radionuclide Industrialization via Electron Accelerator Method

August 12 news, Xi'an Maistop Technology Co., Ltd. recently completed its Pre-A round of financing, with investors including the Central Enterprise Strategic Emerging Fund and Guoxin Venture Capital Fund, both under China Reform Holdings Corporation. The proceeds from this round will primarily be used for site construction, equipment procurement, technology R&D, and daily operations. Founded in 2019, Maistop is a technology enterprise engaged in the R&D and production of medical radionuclides as well as nuclear medicine technical services. The company focuses on the preparation of medical radionuclides via the electron accelerator photonuclear reaction method, with core products including Actinium-225, Lead-212, Copper-67, and Molybdenum-99. Among these, Actinium-225 is a scarce radionuclide of significant interest in alpha-emitting nuclide targeted therapy, with relatively strong global clinical demand...

2026-08-13

Southwest University of Science and Technology Releases Medical Radioactive Waste Treatment Technology Covering Liquid, Gas, and Solid Waste Management

On August 10, the Mianyang Science and Technology City Strategic Development Research Center held an online innovation achievement release conference, unveiling a medical radioactive waste treatment technology developed by the School of National Defense Science and Technology / School of Nuclear Science and Technology at Southwest University of Science and Technology. The technology targets radioactive contaminants including liquid waste, off-gas, and solid waste generated during nuclear medicine diagnosis and treatment, offering a full-chain comprehensive treatment solution. The conference attracted 87,000 experts in the nuclear medicine field, departmental representatives, and enterprise users. With the rapid development of the domestic nuclear medicine industry, insufficient radioactive waste disposal capacity has gradually become a key issue facing the industry's safe expansion. Relevant data show that over 96% of nuclear medicine departments nationwide are constrained by decay tank capacity...

2026-08-13

American Society for Radiation Oncology Foundation to Award $2.4 Million in Grants to 14 Researchers

The American Society for Radiation Oncology (ASTRO) Foundation will award a total of $2.4 million in research grants to 14 scientists dedicated to advancing patient care in radiation medicine. ASTRO stated that the 2026 awards are the first annual grants issued since the society renamed its foundation to LightSpeed—ASTRO Foundation earlier this year. The rebranded foundation will focus on accelerating relevant research and strengthening workforce development in the field of radiation oncology. This round of funding is co-sponsored by the American Cancer Society, the American Association of Physicists in Medicine, the Breast Cancer Research Foundation, the LUNGevity Foundation, and the Prostate Cancer Foundation. ASTRO CEO Vive...

2026-08-13

CGN Hezhi® Proton Therapy System Clinical Performance Successfully Passes Expert Review

On July 31, the expert review meeting for the clinical performance evaluation of the CGN Hezhi® Proton Therapy System was held at the CGN Proton Therapy Equipment Manufacturing Base. Clinical experts from Sun Yat-sen University Cancer Center, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, Sichuan Cancer Hospital, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Hospital, and Shandong First Medical University Affiliated Cancer Hospital attended the review meeting.▲Expert review of CGN Hezhi® Proton Therapy System clinical performanceAt the review meeting, the relevant person in charge of CGN Medical Technology Co., Ltd. (hereinafter referred to as the "Company") introduced that the comprehensive verification platform for the proton therapy system has achieved full-process independent controllability from design, procurement, production,...

2026-08-12

China's First Qualification for Radiation Health Testing and Evaluation of BNCT Equipment Approved

Recently, the Beijing Municipal Health Commission, in accordance with the "Administrative Measures for Radiation Health Technical Service Institutions" (Guoweiban ZhiJian Fa [2026] No. 1), organized experts to conduct on-site reviews of two qualification expansion applications submitted by the National Center for Occupational Safety and Health under the National Health Commission. The projects include performance testing and evaluation of Boron Neutron Capture Therapy (BNCT) equipment and thyroid iodine-131 testing. During the review process, the expert panel conducted a comprehensive examination of the center's management system, personnel allocation, instruments and equipment, and technical capabilities related to radiation health testing and evaluation through document review, technical inquiries, on-site practical operations, and simulated demonstrations...

2026-08-12

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

On August 11, at the Leshan special press conference of "Myriad Scenes in Sichuan · Embarking on the '15th Five-Year Plan'", Leshan Mayor Zhao Yingchun stated that Leshan is accelerating the construction of the largest and most comprehensive medical isotope production base in China. Upon completion, the project will help break the foreign monopoly and import dependence on related products, promote the domestic substitution of anti-cancer nuclear drugs, and enable more patients to access domestically produced drugs with lower prices and better efficacy. Zhao Yingchun noted that during the "14th Five-Year Plan" period, Leshan has focused on building the "China Green Silicon Valley", a world-class tourist destination, and a major regional transportation and logistics hub in the province, continuously promoting high-quality development, with its economic output surpassing 250 billion yuan...

2026-08-12

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

A research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK established a novel geometric imaging principle utilizing positron three-photon decay. Using a gamma-ray measurement system comprising scintillators and silicon photomultipliers (SiPMs), along with the existing PET radiopharmaceutical ^18F-FDG, they successfully visualized the positronium three-photon decay ratio for the first time, completing the proof-of-principle for Positronium Ratio Imaging (PRI). The findings were published in *Communications Physics*. Current clinical nuclear medicine PET examinations primarily utilize gamma rays generated from two-photon annihilation between positrons and electrons to visualize drug accumulation in the body. While this method provides quantitative information on metabolism or drug uptake, it offers limited insight into microenvironmental features such as tissue hypoxia, which are closely related to disease malignancy. In recent years, researchers have attempted to obtain additional tissue information through the average lifetime of positronium formed during positron annihilation, but this approach typically requires the introduction of special nuclides or agents, limiting its practical application.

2026-08-12

LG Electronics Launches FDA-Approved 40-Inch Diagnostic Monitor for B2B Medical Imaging Market

LG Electronics announced on August 12 that it has launched a new 40-inch diagnostic monitor, the 40HT513D, targeting the business-to-business (B2B) medical display market. The product has received approval from the U.S. Food and Drug Administration (FDA) and is primarily intended for medical image interpretation. According to the company, the 40HT513D features a curved IPS black panel with a 21:9 aspect ratio and a resolution of 5120×2160, delivering approximately 11 million pixels. LG Electronics stated that this design consolidates image reading tasks that previously required three 3-megapixel monitors into a single screen. Physicians can simultaneously view and compare current and historical images from X-ray, CT scans, and MRI scans on the same display...

2026-08-12

China Bio-Pharma: Enters Cooperation Agreement with Stella Pharma on Boron Neutron Therapy Drug

China Bio-Pharma Holdings Limited announced on August 12 that the company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., and Japan's Stella Pharma Corporation signed a legally binding Master Cooperation Agreement on August 11, 2026, to jointly advance the development and commercialization of Steboronine in China. Steboronine is described in the announcement as the world's first approved boron neutron therapy drug, applied in Boron Neutron Capture Therapy (BNCT). Under the agreement, the cooperation between the two parties is divided into a development phase and a commercialization phase. During the development phase, the cooperation aims to leverage real-world data, real-world evidence, and real-world studies generated by the China Bio-Pharma Group to facilitate Stella Pharma in obtaining and maintaining, as soon as possible, marketing approval from China's National Medical Products Administration (NMPA) for Steboronine for the treatment of head and neck cancer; after Stella Pharma obtains marketing and manufacturing approval from the Japanese government for Steboronine for meningioma, the relevant China filings may also be extended to the meningioma indication.

2026-08-12

University of Missouri Receives $1 Million Grant to Research New FLASH Radiotherapy System

On August 11, researchers at the University of Missouri School of Medicine received a $1 million grant from the National Institutes of Health to study a new technology in cancer radiotherapy—the TheryQ FLASHKNiFE system. The project is funded through June 2027. A long-standing challenge in cancer treatment is how to kill tumor cells while protecting surrounding healthy tissue as much as possible. Existing radiotherapy can already achieve millimeter-level precision, but radiation damage and related side effects still limit the dose patients can safely receive. Unlike conventional approaches, FLASH radiotherapy does not primarily alter the direction of radiation beams, but instead delivers irradiation in an extremely short time at an ultra-high dose rate...

2026-08-12